212 related articles for article (PubMed ID: 33978392)
1. Nutraceuticals and microbiota.
Díaz-Orozco LE; Méndez-Sánchez N
Minerva Gastroenterol (Torino); 2021 Dec; 67(4):326-338. PubMed ID: 33978392
[TBL] [Abstract][Full Text] [Related]
2. Nutraceuticals in rodent models as potential treatments for human Inflammatory Bowel Disease.
Ghattamaneni NKR; Panchal SK; Brown L
Pharmacol Res; 2018 Jun; 132():99-107. PubMed ID: 29680446
[TBL] [Abstract][Full Text] [Related]
3. Benefit of Dietary Supplementation of Nutraceuticals as an Integrative Approach for Management of Migraine: Evidence From Preclinical and Clinical Studies.
Durham PL; Antonopoulos SR
Curr Pain Headache Rep; 2024 May; 28(5):373-381. PubMed ID: 38430311
[TBL] [Abstract][Full Text] [Related]
4. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease.
Jennison E; Byrne CD
Clin Mol Hepatol; 2021 Jan; 27(1):22-43. PubMed ID: 33291863
[TBL] [Abstract][Full Text] [Related]
5. Microbiota, cirrhosis, and the emerging oral-gut-liver axis.
Acharya C; Sahingur SE; Bajaj JS
JCI Insight; 2017 Oct; 2(19):. PubMed ID: 28978799
[TBL] [Abstract][Full Text] [Related]
6. Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease.
Zhao M; Chen S; Ji X; Shen X; You J; Liang X; Yin H; Zhao L
Pharmacol Res; 2021 Apr; 166():105517. PubMed ID: 33636349
[TBL] [Abstract][Full Text] [Related]
7. Polyphenol and Tannin Nutraceuticals and Their Metabolites: How the Human Gut Microbiota Influences Their Properties.
Fabbrini M; D'Amico F; Barone M; Conti G; Mengoli M; Brigidi P; Turroni S
Biomolecules; 2022 Jun; 12(7):. PubMed ID: 35883431
[TBL] [Abstract][Full Text] [Related]
8. Dysbiosis is one of the risk factor for stroke and cognitive impairment and potential target for treatment.
Koszewicz M; Jaroch J; Brzecka A; Ejma M; Budrewicz S; Mikhaleva LM; Muresanu C; Schield P; Somasundaram SG; Kirkland CE; Avila-Rodriguez M; Aliev G
Pharmacol Res; 2021 Feb; 164():105277. PubMed ID: 33166735
[TBL] [Abstract][Full Text] [Related]
9. The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection.
Stecher B
Microbiol Spectr; 2015 Jun; 3(3):. PubMed ID: 26185088
[TBL] [Abstract][Full Text] [Related]
10. The gut microbiota: A key factor in the therapeutic effects of (poly)phenols.
Espín JC; González-Sarrías A; Tomás-Barberán FA
Biochem Pharmacol; 2017 Sep; 139():82-93. PubMed ID: 28483461
[TBL] [Abstract][Full Text] [Related]
11. Nutraceuticals as modulators of gut microbiota: Role in therapy.
Quigley EMM
Br J Pharmacol; 2020 Mar; 177(6):1351-1362. PubMed ID: 31659751
[TBL] [Abstract][Full Text] [Related]
12. The Role of the Gut Microbiome in Liver Cirrhosis Treatment.
Lee NY; Suk KT
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379148
[TBL] [Abstract][Full Text] [Related]
13. A Comprehensive Review on Nutraceuticals: Therapy Support and Formulation Challenges.
Puri V; Nagpal M; Singh I; Singh M; Dhingra GA; Huanbutta K; Dheer D; Sharma A; Sangnim T
Nutrients; 2022 Nov; 14(21):. PubMed ID: 36364899
[TBL] [Abstract][Full Text] [Related]
14. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms.
Bakhshimoghaddam F; Alizadeh M
Clin Nutr ESPEN; 2021 Aug; 44():61-68. PubMed ID: 34330514
[TBL] [Abstract][Full Text] [Related]
15. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
Zeng Y; Chen S; Fu Y; Wu W; Chen T; Chen J; Yang B; Ou Q
J Viral Hepat; 2020 Feb; 27(2):143-155. PubMed ID: 31600845
[TBL] [Abstract][Full Text] [Related]
16. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer-A review.
Nagasaka M; Sexton R; Alhasan R; Rahman S; Azmi AS; Sukari A
Crit Rev Oncol Hematol; 2020 Jan; 145():102841. PubMed ID: 31884204
[TBL] [Abstract][Full Text] [Related]
18. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
[TBL] [Abstract][Full Text] [Related]
19. When a pandemic and an epidemic collide: COVID-19, gut microbiota, and the double burden of malnutrition.
Littlejohn P; Finlay BB
BMC Med; 2021 Jan; 19(1):31. PubMed ID: 33504332
[TBL] [Abstract][Full Text] [Related]
20. Human gut microbiota/microbiome in health and diseases: a review.
Gomaa EZ
Antonie Van Leeuwenhoek; 2020 Dec; 113(12):2019-2040. PubMed ID: 33136284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
